Review of the Rechargeable Sacral Neuromodulation System to Treat Refractory Overactive Bladder

References

• Haylen BT , de RidderD , FreemanRMet al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int. Urogynecol. J.21(1), 5–26 (2020).
   Google Scholar
• Sacco E . [Physiopathology of overactive bladder syndrome]. Urologia79(1), 24–35 (2012).
   PubMedGoogle Scholar
• Orasanu B , MahajanST. The use of botulinum toxin for the treatment of overactive bladder syndrome. Indian J. Urol.29(1), 2–11 (2013).
   PubMedGoogle Scholar
• Abrams P , CardozoL , FallMet al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am. J. Obstet. Gynecol.187(1), 116–126 (2002).
   PubMed Web of Science ®Google Scholar
• Stewart WF , Van RooyenJB , CundiffGWet al. Prevalence and burden of overactive bladder in the United States. World J. Urol.20(6), 327–336 (2003).
   PubMed Web of Science ®Google Scholar
• Shamliyan T , WymanJ , KaneRL. Nonsurgical treatments for urinary incontinence in adult women: diagnosis and comparative effectiveness. Rockville, MD Report no.:11(12)-EHC074-EF (2012).
   Google Scholar
• Nabi G , CodyJD , EllisGet al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst. Rev.12(12), CD003781 (2006).
   Google Scholar
• Wyman JF , BurgioKL , NewmanDK. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int. J. Clin. Pract.63(8), 1177–1191 (2009).
   PubMed Web of Science ®Google Scholar
• Smith A , BevanD , DouglasHRet al. Management of urinary incontinence in women: summary of updated NICE guidance. BMJ347, f5170 (2013).
   PubMedGoogle Scholar
• Yu YF , NicholMB , YuAPet al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid Program. Value Health8(4), 495–505 (2005).
   PubMed Web of Science ®Google Scholar
• Kalder M , PantazisK , DinasKet al. Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence. Obstet. Gynecol.124(4), 794–800 (2014).
   PubMed Web of Science ®Google Scholar
• Kim TH , LeeKS. Persistence and compliance with medication management in the treatment of overactive bladder. Investig. Clin. Urol.57(2), 84–93 (2016).
   PubMed Web of Science ®Google Scholar
• Gormley EA , LightnerDJ , FaradayMet al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J. Urol.193(5), 1572–1580 (2015).
   PubMed Web of Science ®Google Scholar
• Lightner DJ , GomelskyA , SouterLet al. Diagnosis and treatment of overactive bladder (non-neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. J. Urol.202(3), 558–563 (2019).
   PubMed Web of Science ®Google Scholar
• Bartley J , GilleranJ , PetersK. Neuromodulation for overactive bladder. Nat. Rev. Urol.10(9), 513–521 (2013).
   PubMed Web of Science ®Google Scholar
• Karademir K , BaykalK , SenBet al. A peripheric neuromodulation technique for curing detrusor overactivity: stoller afferent neurostimulation. Scand. J. Urol. Nephrol.39(3), 230–233 (2005).
   PubMed Web of Science ®Google Scholar
• Nitti VW , DmochowskiR , HerschornSet al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a Phase III, randomized, placebo controlled trial. J. Urol.189(6), 2186–2193 (2013).
   PubMed Web of Science ®Google Scholar
• Rai BP , CodyJD , AlhassoAet al. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst. Rev.12(12), CD003193 (2012).
   PubMedGoogle Scholar
• Starkman JS , SmithCP , StaskinDR. Surgical options for drug-refractory overactive bladder patients. Rev. Urol.12(2–3), e97–e110 (2010).
   PubMedGoogle Scholar
• Staskin DR , PetersKM , MacDiarmidSet al. Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care. Curr. Urol. Rep.13(5), 327–334 (2012).
   PubMed Web of Science ®Google Scholar
• Gormley EA , LightnerDJ , BurgioKLet al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J. Urol.188(6), 2455–2463 (2012).
   PubMed Web of Science ®Google Scholar
• Pettit PD , ThompsonJR , ChenAH. Sacral neuromodulation: new applications in the treatment of female pelvic floor dysfunction. Curr. Opin. Obstet. Gynecol.14, 521–525 (2002).
   PubMed Web of Science ®Google Scholar
• Hohenfellner M , Schultz-LampelD , DahmsSet al. Bilateral chronic sacral neuromodulation for treatment of lower urinary tract dysfunction. J. Urol.160, 821–824 (1998).
   PubMed Web of Science ®Google Scholar
• de Groat WC , TaiC. Neuromodulation. Chapter 19 Mechanisms of action of sacral nerve and peripheral nerve stimulation for disorders of the bladder and bowel. 221–236 (2018). https://app.dimensions.ai/details/publication/pub.1100746557 doi:10.1016/b978-0-12-805353-9.00019-x
   Google Scholar
• DasGupta R , FowlerCJ. The management of female voiding dysfunction: Fowler’s syndrome – a contemporary update. Curr. Opin. Urol.13, 293–299 (2003).
   PubMed Web of Science ®Google Scholar
• Osman NI , ChappleCR. Fowler’s syndrome – a cause of unexplained urinary retention in young women?Nat. Rev. Urol.11, 87–98 (2014).
   PubMed Web of Science ®Google Scholar
• Janknegt RA , WeilEH , EerdmansPH. Improving neuromodulation technique for refractory voiding dysfunctions: two-stage implant. Urology49, 358–362 (1997).
   PubMed Web of Science ®Google Scholar
• Baxter C , KimJH. Contrasting the percutaneous nerve evaluation versus staged implantation in sacral neuromodulation. Curr. Urol. Rep.11, 310–314 (2010).
   PubMedGoogle Scholar
• Everaert K , KerckhaertW , CaluwaertsHet al. A prospective randomized trial comparing the 1-stage with the 2-stage implantation of a pulse generator in patients with pelvic floor dysfunction selected for sacral nerve stimulation. Eur. Urol.45, 649–654 (2004).
   PubMed Web of Science ®Google Scholar
• InterStim II System. (2020). www.medtronic.com/us-en/healthcare-professionals/products/urology/sacral-neuromodulation-systems/interstim-ii.html?cmpid=MDT_SacralNeuroSystm_interstim_Redirect_MDT_Com_SacrlNeuroSystm_interstimii_RTG_PelvicHealth_Migration_FY20
   Google Scholar
• McCrery R , LaneF , BensonKet al. Treatment of urinary urgency incontinence using a rechargeable SNM system: 6-month results of the ARTISAN-SNM Study. J. Urol.203, 185–192 (2020).
   PubMedGoogle Scholar
• Administration US Food and Drug Administration . Axonics sacral neuromodulation (SNM) system for urinary control – P180046. (2020). www.fda.gov/medical-devices/recently-approved-devices/axonics-sacral-neuromodulation-snm-system-urinary-control-p180046
   Google Scholar
• Elterman DS . The novel Axonics(R) rechargeable sacral neuromodulation system: procedural and technical impressions from an initial North American experience. Neurourol. Urodyn.37, S1–S8 (2018).
   PubMed Web of Science ®Google Scholar
• Blok B , Van KerrebroeckP , de WachterSet al. Programming settings and recharge interval in a prospective study of a rechargeable sacral neuromodulation system for the treatment of overactive bladder. Neurourol. Urodyn.37, S17–S22 (2018).
   PubMed Web of Science ®Google Scholar
• Jottard K , Vanden Broeck S , KomenNet al. Treatment of fecal incontinence with a rechargeable sacral neuromodulation system: efficacy, clinical outcome, and ease of use-six-month follow-up. Neuromodulation (2020).doi:10.1111/ner.13298 ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Benson K , McCreryR , TaylorCet al. One-year outcomes of the ARTISAN-SNM study with the Axonics System for the treatment of urinary urgency incontinence. Neurourol. Urodyn.39, 1482–1488 (2020).
   PubMed Web of Science ®Google Scholar
• Pezzella A , McCreryR , LaneFet al. Two-year outcomes of the ARTISAN-SNM study for the treatment of urinary urgency incontinence using the Axonics rechargeable sacral neuromodulation system. Neurourol. Urodyn.40, 714–721 (2021).
   PubMed Web of Science ®Google Scholar
• Blok B , Van KerrebroeckP , de WachterSet al. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system. Neurourol Urodyn.39, 1108–1114 (2020).
   PubMed Web of Science ®Google Scholar